344 related articles for article (PubMed ID: 32469279)
1. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
2. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M
Kumar V; Dhanjal JK; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2021 Jul; 39(11):3842-3854. PubMed ID: 32431217
[TBL] [Abstract][Full Text] [Related]
3. Anti-COVID-19 Potential of Withaferin-A and Caffeic Acid Phenethyl Ester.
Kumar V; Sari AN; Gupta D; Ishida Y; Terao K; Kaul SC; Vrati S; Sundar D; Wadhwa R
Curr Top Med Chem; 2024; 24(9):830-842. PubMed ID: 38279743
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
5. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of anti-SARS-CoV2 activity of Ashwagandha-derived withanolides.
Dhanjal JK; Kumar V; Garg S; Subramani C; Agarwal S; Wang J; Zhang H; Kaul A; Kalra RS; Kaul SC; Vrati S; Sundar D; Wadhwa R
Int J Biol Macromol; 2021 Aug; 184():297-312. PubMed ID: 34118289
[TBL] [Abstract][Full Text] [Related]
7. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H
Molecules; 2020 May; 25(10):. PubMed ID: 32408547
[TBL] [Abstract][Full Text] [Related]
8. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
[TBL] [Abstract][Full Text] [Related]
9. Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.
M P; Reddy GJ; Hema K; Dodoala S; Koganti B
Eur J Pharmacol; 2021 Jan; 890():173688. PubMed ID: 33130280
[TBL] [Abstract][Full Text] [Related]
10. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.
Shirato K; Kawase M; Matsuyama S
J Virol; 2013 Dec; 87(23):12552-61. PubMed ID: 24027332
[TBL] [Abstract][Full Text] [Related]
11. Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies.
Kishk SM; Kishk RM; Yassen ASA; Nafie MS; Nemr NA; ElMasry G; Al-Rejaie S; Simons C
Molecules; 2020 Oct; 25(21):. PubMed ID: 33137894
[TBL] [Abstract][Full Text] [Related]
12. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
13. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry.
Moumbock AFA; Tran HTT; Lamy E; Günther S
Arch Pharm (Weinheim); 2023 Jan; 356(1):e2200371. PubMed ID: 36316225
[TBL] [Abstract][Full Text] [Related]
14. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.
Mahmoud IS; Jarrar YB
Mol Biol Rep; 2021 May; 48(5):4667-4675. PubMed ID: 34023987
[TBL] [Abstract][Full Text] [Related]
15. The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.
Wettstein L; Kirchhoff F; Münch J
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163273
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
17. Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures.
Guo W; Porter LM; Crozier TW; Coates M; Jha A; McKie M; Nathan JA; Lehner PJ; Greenwood EJ; McCaughan F
Life Sci Alliance; 2022 Apr; 5(4):. PubMed ID: 35110354
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
[TBL] [Abstract][Full Text] [Related]
20. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).
Barge S; Jade D; Gosavi G; Talukdar NC; Borah J
Eur J Pharm Sci; 2021 Jul; 162():105820. PubMed ID: 33775827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
